Comparative characteristics of some haematological and biochemical indicators in II–III stages cervix cancer patients with late radiation complications in treatment dynamics
Authors: Sevastianova V. S. , Hladkykh F. V. , Kulinich H. V. 
Published: February 2021

Depending on the stage of the process, tactics for the treatment of cervical cancer (СС) may include surgical treatment, radiation therapy (RT), chemotherapy, hormone therapy and a combination of these methods. The leading place in the treatment of patients with cancer is today occupied by combined RT. However, despite improvements in methodological approaches to RT, the problem of side effects of radiation treatment – early and late radiation complications (LRC) still remains to be fully resolved.

Purpose of the study. To carry out comparative analysis of individual hematological and biochemical parameters of peripheral blood (hematocrit, fibrinogen, aspartate aminotransferase (AsAt, urea and total protein) of patients with II and III stage of CC before and after RT.

Materials and methods. A retrospective analysis of case histories of patients with stage II–III cervical cancer was performed. The main group – 102 people: 68 patients with stage II cervical cancer and 34 patients with stage III cervical cancer with LRC. Control group: 90 people – 46 patients with stage II cervical cancer and 44 patients with stage III cervical cancer without LRC.

Results. The study showed that in patients with СС with LRC were higher baseline (before RT) hematocrit indicators by 5,8% (p = 0,3) in patients with II stage of CC and by 11,4% (p = 0,02) in patients with III stage of СС relative to baseline indices of CC-patients without LRC and were respectively 36,2% and 35,2%. Analysis of the level of fibrinogen showed that patients with II stage of СС this indicator before RT was statistically significant (p = 0,04) higher by 10.3% in patients with LRC and was 3,2 g/L, respectively. In patients with III stage of CC with LRC, the same indicator for RT was on the contrary lower by 8,3% (p = 0,5) relative to the indicators of patients without LRC. It was found that baseline AsAt in patients with СС was higher in patients with LRC, respectively, by 12,2% in patients with II stage of CC (p  0,05) and 18,5% (p < 0,01) in patients with III stage of CC. Noteworthy is the statistically probable (p < 0,05) increase in urea level in patients with CC after RP: by 25,6% in patients with II stage of СС and by 24,5% in patients with III stage of CC, which differs from the dynamics to a decrease in the same indicator in patients with cervical cancer without LRC (by 22,6% and 1,9% in patients with II and III stage of CC respectively). Characterizing the level of total protein in patients with II–III stage of CC it is worth noting that in patients with LRC, the baseline values of the indicated indicator are statistically significantly (p < 0,05) higher than the similar indicators of patients without LRC by 5,5% and 6,4%, respectively, in the II stage of CC and the III stage of CC.

Conclusions. Input indicators of hematocrit level in patients with III stage of CC with LRC statistically significant (p = 0,02) by 11,4% exceeded the corresponding figure in patients without LRC. The level of AsAt before RT in patients with III stage of CC with LRC statistically significantly (p < 0,01) exceeded by 18,5% the same indicator of patients without LRS, and after RT it tended to increase by 22,4%. It is established that patients with II and III stage of CC after RT, statistically significant (p < 0,05) increase of urea level by 25,6% and 24,5% respectively was noted.